cagrisema semaglutide cagrilintide phase 3 results 2024 2025 Three new REIMAGINE studies provide some of the strongest evidence yet for CagriSema® (cagrilintide + semaglutide) in type 2 diabetes. 🔹 REIMAGINE 1 Studied people with early type 2 diabetes Novo's CagriSema loses phase 3

For best results, follow with a soothing mask or hydrating serum

While reduced appetite is completely normal on GLP-1s, skipping meals entirely is not recommended

Compounded GLP-1s from a licensed pharmacy should be consistent batch to batch

If results remain strong across the program, many analysts expect retatrutide to become one of the most commercially significant peptide therapeutics ever developed

No worldwide marketing authorization, FDA IND status, WADA class S2

While mild changes in sweating patterns may not require immediate medical attention, certain symptoms warrant prompt evaluation by your healthcare provider